Scarica l'app Stockscreener
55.03
2.83%
-1.60
Dopo l'orario di chiusura:
55.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BBIO Giù?
Forum
Previsione
Precedente Chiudi:
$56.63
Aprire:
$56.78
Volume 24 ore:
1.18M
Relative Volume:
0.50
Capitalizzazione di mercato:
$10.52B
Reddito:
$217.77M
Utile/perdita netta:
$-438.86M
Rapporto P/E:
-22.83
EPS:
-2.41
Flusso di cassa netto:
$-456.33M
1 W Prestazione:
+0.44%
1M Prestazione:
+6.88%
6M Prestazione:
+62.57%
1 anno Prestazione:
+108.92%
Intervallo 1D:
$54.49
$56.80
Intervallo di 1 settimana:
$54.49
$57.49
Portata 52W:
$21.72
$57.49
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Nome
Bridgebio Pharma Inc
Settore
Industria
Telefono
(650) 391-9740
Indirizzo
3160 PORTER DR., PALO ALTO, CA
Confronta BBIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
55.03 | 10.80B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-30 | Ripresa | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-14 | Iniziato | Jefferies | Buy |
| 2025-07-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-06-17 | Iniziato | Wolfe Research | Outperform |
| 2025-03-31 | Iniziato | Redburn Atlantic | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-03 | Iniziato | Oppenheimer | Perform |
| 2024-09-04 | Iniziato | Piper Sandler | Overweight |
| 2024-03-21 | Ripresa | Raymond James | Outperform |
| 2024-01-31 | Iniziato | BMO Capital Markets | Market Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-11-07 | Iniziato | Citigroup | Buy |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-07-18 | Downgrade | Jefferies | Buy → Hold |
| 2023-04-19 | Iniziato | Evercore ISI | Outperform |
| 2023-02-06 | Iniziato | Cowen | Outperform |
| 2021-12-27 | Reiterato | Mizuho | Buy |
| 2021-12-27 | Reiterato | SVB Leerink | Outperform |
| 2021-09-10 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-03-22 | Reiterato | Goldman | Buy |
| 2021-02-22 | Ripresa | JP Morgan | Overweight |
| 2021-02-09 | Ripresa | Goldman | Buy |
| 2021-01-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-10 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-25 | Iniziato | BofA/Merrill | Neutral |
| 2020-05-19 | Iniziato | BTIG Research | Buy |
| 2020-04-13 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-19 | Iniziato | Mizuho | Buy |
| 2019-07-26 | Iniziato | Raymond James | Outperform |
| 2019-07-22 | Iniziato | BMO Capital Markets | Outperform |
| 2019-07-22 | Iniziato | Goldman | Buy |
| 2019-07-22 | Iniziato | JP Morgan | Overweight |
| 2019-07-22 | Iniziato | Jefferies | Buy |
| 2019-07-22 | Iniziato | Piper Jaffray | Overweight |
| 2019-07-22 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Bridgebio Pharma Inc Borsa (BBIO) Ultime notizie
(BBIO) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Achondroplasia Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | BioMarin Pharmaceuticals, BridgeBio/ QED Therapeutics, Ribomic Inc, Sanofi - The Globe and Mail
BridgeBio Pharma Hits New 52-Week High of $57.47, Up 103% - Markets Mojo
Published on: 2025-10-15 10:59:59 - newser.com
Sentiment analysis tools applied to BridgeBio Pharma Inc.Trade Risk Assessment & Weekly High Conviction Ideas - newser.com
BridgeBio Pharma Hits New 52-Week High of $56.24, Up 101% Yearly - Markets Mojo
How big funds are accumulating BridgeBio Pharma Inc. (2CL) stockAnalyst Downgrade & Safe Capital Growth Plans - newser.com
BridgeBio Pharma stock hits 52-week high at 56.28 USD - Investing.com
Will BridgeBio Pharma Inc. bounce back from current support2025 Market Outlook & Expert Curated Trade Setups - newser.com
BridgeBio Pharma Inc. stock trend outlook and recovery pathWeekly Trend Summary & Free Expert Approved Momentum Trade Ideas - newser.com
Long term hold vs stop loss in BridgeBio Pharma Inc.Trade Exit Summary & Verified Short-Term Plans - newser.com
How buybacks impact BridgeBio Pharma Inc. stock valueInsider Selling & Daily Market Momentum Tracking - newser.com
BridgeBio Pharma, Inc. (BBIO) Stock Analysis: Unlocking Potential with a 19.51% Upside and Revolutionary Biotech Ventures - DirectorsTalk Interviews
What indicators show strength in BridgeBio Pharma Inc.Index Update & Reliable Price Breakout Alerts - newser.com
BridgeBio Pharma Hits New 52-Week High of $55.13, Up 94.83% - Markets Mojo
BridgeBio (BBIO) Leads Biotech Sector with Promising Pipeline - GuruFocus
SA Asks: What's the most attractive biotech stock right now? - Seeking Alpha
Oak Ridge Investments LLC Purchases New Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Published on: 2025-10-12 03:32:49 - newser.com
BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar Sells 40,000 Shares - MarketBeat
Using flow based indicators on BridgeBio Pharma Inc.2025 Analyst Calls & Consistent Profit Trading Strategies - newser.com
Why BridgeBio Pharma Inc. (2CL) stock could outperform next yearJuly 2025 Breakouts & AI Based Trade Execution Alerts - newser.com
BridgeBio Pharma (NASDAQ:BBIO) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
BridgeBio Pharma Hits New 52-Week High of $55.33, Up 98.71% - Markets Mojo
Using economic indicators to assess BridgeBio Pharma Inc. potentialJuly 2025 Intraday Action & Daily Chart Pattern Signals - newser.com
Leading vs lagging indicators on BridgeBio Pharma Inc. performance2025 Momentum Check & Free Fast Entry Momentum Trade Alerts - newser.com
Real time breakdown of BridgeBio Pharma Inc. stock performanceIPO Watch & Risk Managed Investment Signals - newser.com
Will breakout in BridgeBio Pharma Inc. lead to full recoveryJuly 2025 Intraday Action & Growth Focused Entry Point Reports - newser.com
BridgeBio Pharma, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
BridgeBio Pharma Hits New 52-Week High of $54.64, Up 96.23% - Markets Mojo
BridgeBio Pharma (NASDAQ:BBIO) Sets New 12-Month HighHere's What Happened - MarketBeat
BridgeBio Pharma stock hits 52-week high at $54.61 By Investing.com - Investing.com South Africa
BridgeBio Pharma stock hits 52-week high at $54.61 - Investing.com
Analyzing drawdowns of BridgeBio Pharma Inc. with statistical toolsJuly 2025 Decliners & Fast Gaining Stock Strategy Reports - newser.com
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(4) - MarketScreener
PFG Investments LLC Takes Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
What MACD and RSI say about BridgeBio Pharma Inc.Weekly Market Outlook & Target Return Focused Stock Picks - newser.com
Pattern recognition hints at BridgeBio Pharma Inc. upsideJuly 2025 EndofMonth & Pattern Based Trade Signal System - newser.com
BridgeBio Pharma (BBIO) Is Up 5.6% After Acoramidis Shows Broad ATTR-CM Benefit in Phase 3 Data - Yahoo
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BridgeBio Pharma reports inducement grants under Nasdaq Listing Rule - MarketScreener
23,884 RSUs: BridgeBio Grants Inducement Shares with Quarterly Vesting Starting Nov. 16, 2026 - Stock Titan
What earnings revisions data tells us about BridgeBio Pharma Inc.2025 Geopolitical Influence & Daily Risk Controlled Trade Plans - newser.com
Bridgebio Pharma Inc Azioni (BBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Bridgebio Pharma Inc Azioni (BBIO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kumar Neil | Chief Executive Officer |
Oct 08 '25 |
Sale |
54.78 |
40,000 |
2,191,350 |
855,686 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):